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ABSTRACT
Background: There is only limited information about cost-effectiveness of
drug-eluting compared with bare metal stents (BMS) over a time horizon
of more than 1 year.
Methods and Results: We developed a Markov model based on clinical
outcome data from a meta-analysis including 17 randomized controlled
trials comparing drug-eluting versus BMS with a minimum follow-up of 1
(n = 8221) and a maximum follow-up of 3 years (n = 4105) in patients with
chronic coronary artery disease. Costs were obtained as reimbursement
rates for diagnosis related groups from the US Centers for Medicare and
Medicaid Services. All costs and effects were discounted at 3% annually. All
costs are reported in US dollars of the ﬁnancial year 2007. The incremental
effects are 0.002 (95% conﬁdence interval -0.039 to 0.041) quality-
adjusted life-years (QALYs) for the sirolimus- and -0.001 (-0.040 to 0.038)
QALYs for the paclitaxel-eluting stents (PES). The incremental costs are
$2790 for the sirolimus- and $3838 for the PES. The incremental cost-
effectiveness ratio is >$1,000,000 per QALY for the sirolimus-eluting stent.
PES are dominated by BMS (i.e., less effective and more costly). Among
various sensitivity analyses performed, the model proved to be robust.
Conclusions: Our analysis from a US Medicare perspective suggests that
drug-eluting stents are not cost-effective compared with BMS when
implanted in unselected patients with symptomatic ischemic coronary
artery disease.
Keywords: cardiology, cost-utility analysis, decision-analytic model, drug-
eluting stents.
Introduction
The economic burden of cardiovascular disease is substantial. In
the year 2006, health-care spending and lost productivity from
cardiovascular disease exceeded $400 billion in the United States
[1]. Among patients with coronary artery disease, stent implan-
tation has become the treatment of choice in the last decade [2,3].
Currently, nearly 80% of all inserted stents in the United States
are drug-eluting stents (DES) [4]. It is estimated that the world
market for DES sums up to $6 billion annually [5].
In recently published meta-analyses of randomized controlled
trials (RCTs) comparing bare metal with DES, DES were found
to reduce restenoses and the need for revascularization proce-
dures, but not overall mortality or the incidence of myocardial
infarction (MI) [6–12].
As with many new interventions, there is a signiﬁcant price
premium on DES when compared with conventional bare metal
stents (BMS). Limited health-care budgets increase the incentive
to not only look at the clinical effectiveness of an intervention but
also to take into account the cost-effectiveness of a novel therapy.
Several economic evaluations of DES exist to date, some of
which are directly based on clinical trials and others on model-
based economic evaluations [9,13–18]. Nevertheless, there still
remains a considerable controversy about the cost-effectiveness
of DES when compared with BMS for all patients undergoing
percutaneous coronary intervention (PCI) [19,20].
In a recent systematic review, Lightart and colleagues identi-
ﬁed 19 cost-effectiveness studies of DES that were published
between January 2000 and July 2006 [5]. In their conclusions, 10
studies were in favor, whereas 9 studies were not in favor of
widespread use of DES. Five of the 19 studies were performed
from a US third-party payer perspective, and favored the wide-
spread use of DES [21–25]. All studies from the United States
used a short time horizon, with maximum clinical follow-up of 1
year, and thus disregarded potential differences in other patient-
relevant outcomes, as well as quality of life estimates that may
arise beyond the ﬁrst year after stent implantation. Other studies
used a single trial as a vehicle for the economic evaluation that
will often lead to a partial and limited analysis [26].
To provide a more thorough answer to the question whether
the routine use of DES is cost-effective for the treatment of
coronary artery disease from a US Medicare payer’s perspective,
we developed a decision-analytic model based on recently pub-
lished data of long-term outcomes of RCTs comparing DES with
BMS. We developed a model that allows for a probabilistic
sensitivity analysis to address the joint implications of parameter
uncertainty (i.e., uncertainty about the input data) on the uncer-
tainty relating to the decision whether a novel technology is
cost-effective [26].
Methods
A half-cycle corrected Markov cohort simulation model with the
ﬁve mutually exclusive health states stent, nonfatal MI, PCI,
coronary artery bypass graft surgery (CABG), and death was
developed (Fig. 1) [27]. We compared both DES versus BMS.
Because baseline event rates differed in the two BMS groups, we
calculated the pooled event rates weighted by the number of
patients in the BMS trial arms. The transition probabilities from
the index procedure to death, nonfatal MI, clinically driven PCI,
and CABG were derived from an updated, previously published
meta-analysis of RCTs comparing sirolimus-eluting stents (SES)
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or paclitaxel-eluting stents (PES) with BMS in patients with
coronary artery disease [11]. Brieﬂy, trials were required to
report mortality data after at least 1 year of follow-up. Trials
exclusively including patients with acute coronary syndromes or
trials focusing on interventions in nonnative coronary arteries
were excluded because these trials evaluate a different patient
population. We conducted a systematic literature search of
MEDLINE, Embase, Web of Science, and the Cochrane Library
websites dedicated to the dissemination of results from cardio-
vascular trials from January 1980 up to April 2006 and con-
tacted the manufacturers of SES and PES. We identiﬁed 17 trials
including 8221 patients that fulﬁlled inclusion criteria. Seven
trials used SES (n = 2487), nine trials (n = 4908) PES, and one
trial [15] used (n = 826) both DES. Twelve trials including 4631
patients reported outcome data after 2 years, nine trials including
4105 patients reported outcome data after 3 years. Details on the
selection process for potentially eligible trials, the characteristics
and quality of included trials, and on the generation of summary
estimates are provided in the Appendix and have been published
elsewhere [11].
The cycle length in the model is 1 month to allow for a precise
estimation of the timing of events and related cost. The study’s
perspective is a US Medicare payer’s perspective. Estimates for all
parameters where there was no data available from our meta-
analysis were derived from a systematic search of the medical
literature. All costs and effects were discounted at 3% annually
using monthly compounding.
Clinical Parameters
Transition probabilities are of central importance in a Markov
model. The transition probabilities from the stent state to the
health states MI, PCI, CABG, and death were obtained by trans-
forming point estimates for event rates and their corresponding
standard deviations into monthly probabilities (for 0–30 days
after the index procedure, for 30 days to 1 year, for year 1–2, and
for year 2–3; for details, see Appendix Tables 1, 2, and 3) [27].
PCI was deﬁned as any percutaneous target vessel revasculariza-
tion. From the meta-analysis, outcome data were available for
the time period 30 days following the initial stenting procedure,
and for the years 1, 2, and 3 after the index procedure. Likewise,
we obtained values for the relative risks for the same transitions.
We used the method of moments ﬁtting [28] to ﬁt beta distribu-
tions to the transition probabilities derived from the meta-
analysis, and ﬁtted lognormal distributions to all relative risk
parameters in the model. The remaining transition probabilities
were taken from published studies [29–34] and are provided in
Table 1. We assumed that the transition probabilities from the
PCI state to the health states MI, CABG, and death were the
same as for patients in the “stent” state.
Costs
All costs in the model were obtained as reimbursement rates for
diagnosis-related groups (DRGs) from the US Centers for Medi-
care and Medicaid Services [35]. We used reimbursement rates for
the DRGs 121 and 122 (circulatory disorders with acute myocar-
dial infarction with/without major complications discharged
alive), 547–550 (coronary bypass with/without cardiac catheter-
ization with/without major cardiovascular diagnosis [CV DX]),
556 (PCI with non-DES without CV DX), and 557 and 558 (PCI
Figure 1 State-transition diagram.Not shown are the transitions to the death
state. CABG, coronary artery bypass graft surgery; MI, myocardial infarction;
PCI, percutaneous coronary intervention.
Table 1 Model parameters
Parameter Mean (SD) base-case* Distribution
Source
base-case
Mean (SD) sensitivity
analysis*
Source sensitivity
analysis
Transition probabilities
MI → Death (30 days) 0.13 — [30] — —
MI → Death (after 30 days) 0.00569 — [30] — —
CABG → Death (30 days) 0.015 — [36] — —
CABG → Death (after 30 days) 0.00255 — [36] — —
CABG → MI (ﬁrst 30 days) 0.0276 — [32] — —
CABG → MI (after 30 days) 0.00077218 — [32] — —
Disutilities (QALYs)
MI 0.0104 (0.00047) Beta [3] 0.00658 [39]
PCI 0.0104 (0.00047) Beta [3] 0.00658 [39]
CABG 0.0208 (0.00063) Beta [3] 0.00658 [39]
Costs (US dollars)
PCI with BMS 18,469 (3,781) Gamma [35] 14,609 (2,602) [35]
PCI with DES 24,536 (5,042) Gamma [35] 18,429 (2,910) [35]
Acute MI 15,999 (3,851) Gamma [35] 11,150 (1,704) [35]
CABG 51,050 (10,972) Gamma [35] 37,576 (5,882) [35]
Transition probabilities are shown as monthly probabilities.
SD, standard deviation; MI, nonfatal myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
Cost data for the base-case represent average DRG reimbursement rates for the following 10 top-rated US hospitals: Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; Brigham
andWomen’s Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA;Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston,TX; Duke University Medical Center, Durham,
NC; Stanford Hospital and Clinics, Stanford, CA; Barnes-Jewish Hospital/Washington University, St. Louis, MO; UCLA Medical Center, Los Angeles, CA; William Beaumont Hospital, Royal
Oak, MI.
Cost data for the base-case represent average DRG reimbursement rates for the following 10 randomly chosen US hospitals: Northern Michigan Hospital, Petoskey, MI; Manchester
Memorial Hospital, Manchester, CT; Reynolds Memorial Hospital Inc., Glen Dale,WV; Metrowest Medical Center, Natick, MA; Saint Luke’s Hospital of Kansas City, Kansas City, MO;Whittier
Hospital Medical Center, Whittier, CA; Sumter Regional Hospital, Americus, GA; St. Mary’s Hospital, Centralia, IL; Alexian Brothers Medical Center, Elk Grove Village, IL; Madison County
Hospital, London, OH.
650 Bischof et al.
with DES with/without major CV DX). Reimbursement rates for
DES are independent of the type of DES used. For events where
more than one DRG was available (i.e., cases with and without
complications), we combined the costs from all relevant DRGs
weighted by the number of cases in 2006 [35]. We assumed that
physician fees would account for the same percentage share per
event as reported by Mahoney et al. [36]. For our base case, we
used average Medicare reimbursement rates of 10 top-rated car-
diology hospitals in the United States [37]; in a sensitivity analysis,
we used average reimbursement rates from a random sample of 10
US hospitals from the same source [35]. Costs are provided in
Table 1. We assumed that there would be no difference in resource
use for antiplatelet medication because clopidogrel or ticlopidine
were used for the same time period in patients treated with DES
and BMS in all trials of the meta-analysis. Thus, costs for medi-
cations and follow-up visits were not included into the model.
Based on data for our sample of US hospitals, we ﬁtted
gamma distributions to reﬂect parameter uncertainty of the unit
costs of the procedures. All costs are reported in US dollars of the
ﬁnancial year 2007.
Outcomes
The outcome of the two strategies was measured in natural units
and quality-adjusted life-years (QALYs). This generic instrument
weighs the length of life by the quality of life a patient has while
being in a speciﬁc health state. QALYs combine both, morbidity,
and mortality into a single parameter, and therefore allow com-
paring the effect of treatments across different disease areas.
We calculated QALYs using the approach by Bagust et al. [14].
We assumed a baseline quality of life value of 0.86 for patients
without an event. We estimated disutility values (i.e., a short-term
drop in patients’ quality of life) for patients with PCI and CABG
(Table 1) based on the results of the Arterial Revascularization
Therapy Study (ARTS) trial. In this trial, quality of life values were
obtained based on the EuroQol 5 Dimensions (EQ-5D) question-
naire at baseline and 1, 6, and 12 months after stenting or CABG
surgery for coronary artery disease [3]. We calculated the disutility
values by taking the difference in health-related quality of life
values between a patient with and without an event. Thus, the
calculated disutility values reﬂect the loss in patients’ quality of life
for up to 6 months after the event. No loss in quality of life was
assumed to occur 6 months after the event. For patients experi-
encing a myocardial infarction, we attributed an ongoing disutility
of 0.01 per month starting at the time of the event until end of
follow-up based on a community-based study reporting self-
perceived quality of life after myocardial infarction [38]. In a
sensitivity analysis, we used disutility values per event as reported
in a health-technology assessment from the United Kingdom on
the use of coronary artery stents [39] disregarding the patients’
loss in quality of life because of long waiting time (which generally
does not apply to patients in a US Medicare setting).
Analysis
Total costs of the two strategies and the corresponding outcomes
as number of QALYs experienced were recorded. The result of
the analysis is expressed as the incremental net monetary beneﬁt
(INMB) for DES when compared with BMS for two different
threshold values ($50,000 and $100,000) [40]. The INMB is
calculated by the following standard equation:
INMB effect threshold value costs= × −Δ Δ
INMB is therefore the difference in treatment effect of DES
(incremental effect) multiplied by the willingness to pay (i.e.,
threshold value) per one unit of outcome gained (i.e., per QALY)
minus the incremental (i.e., additional) net total health-care costs
for providing DES. By multiplying the incremental effect with the
threshold value, the effect is transformed into a monetary unit.
For the base-case analysis, we assumed an arbitrary decision-
maker’s willingness-to-pay of $100,000 per QALY. A positive
INMB reﬂects that the intervention under analysis is cost-
effective. The INMB approach yields the same results as when
calculating the incremental cost-effectiveness ratio. Nevertheless,
the INMB approach avoids the potential problem of averaging
over positive and negative incremental effects and costs that may
arise when performing a probabilistic sensitivity analysis with
multiple iterations.
For the base-case analysis, we performed a probabilistic sen-
sitivity analysis with 5000 Monte Carlo simulations [41,42] to
account for parameter uncertainty that relates to the uncertainty
in the analysis arising from the lack of deﬁnite knowledge about
a parameter’s true value. We tested the robustness of the model
toward model assumptions with univariate sensitivity analysis on
estimates of clinical effectiveness, on different time horizons, on
the difference of DRG reimbursement rates for BMS and DES, on
health state utilities, on costs of PCI, MI, and CABG, and on
discount rates for costs and health effects. Because published data
on the need for percutaneous coronary reinterventions report
censored data after one event, but some patients have multiple
interventions, we conducted an additional sensitivity analysis on
the number of patients undergoing multiple percutaneous coro-
nary reinterventions. Based on data from the Basel Stent Kosten
Effektivitaets Trial (BASKET) [15], we assumed that there are
about 5% more percutaneous interventions due to multiple inter-
ventions in individual patients. The model was developed with
Microsoft EXCEL and Microsoft Visual Basic 6.5 (Microsoft
Corporation, Redmond, WA).
Results
From the PSA, it was calculated that 19.01% of BMS patients
require probability sensitivity analysis (PSA) a repeat PCI com-
pared with 8.55% of SES patients and 12.44% of PES patients.
The incidence of MIs over the 3-year time horizon is 4.29% in
BMS patients, and 3.23% in SES, and 3.83% in PES patients.
Likewise the incidence of CABG is lower in the DES group (BMS:
3.68%, SES: 2.44%, PES 2.49%). Mortality is slightly increased
in SES and PES patients (BMS: 4.36%, SES: 4.49%, PES 4.92%).
The incremental effects of the DES are 0.002 (95% conﬁ-
dence interval [CI] -0.039 to 0.041) QALYs for the sirolimus-
and -0.001 (95% CI -0.040 to 0.038) QALYs for the PES. The
incremental costs are $2790 for SES and $3838 for PES.
This yields an incremental cost-effectiveness ratio of
>$1,000,000 for SES. PES are dominated by BMS (i.e., PES are
less effective and more costly). Table 2 provides the expected
costs and health effects for the base-case analysis.
The uncertainty for the decision is graphically represented on
the cost-effectiveness plane (Fig. 2). Cost-effectiveness accept-
ability curves provide an estimate of the probability that DES are
cost-effective for a range of different willingness-to-pay values
(Fig. 3). At an arbitrary willingness-to-pay of $100,000 per
QALY, SES have a 8.3% probability, and PES a 2.8% probability
of being cost-effective.
Univariate Sensitivity Analysis
In individual patient data meta-analyses comparing DES with
BMS [6,8], there were no signiﬁcant differences in the rates of
death and myocardial infarction. Given the uncertainty around
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the point estimates of the relative risks for these outcomes in our
meta-analysis, we conducted a sensitivity analysis assuming no
difference in the number of deaths between patients treated with
BMS and DES (Table 3). Both DES then yield a small positive
incremental effect, but the INMBs still remain negative. At an
arbitrary willingness-to-pay of $100,000 per QALY, the INMB
is then -$2360 for SES and -$3708 for PES, respectively.
Accounting for multiple PCIs in individual patients had no quali-
tative effect on the overall cost-effectiveness estimates, neither for
SES nor for PES. To explore the effect of different time horizons,
we calculated the incremental effect for time horizons up to 3
years (Fig. 4). Both DES provide positive incremental effects (in
QALYs) over a time horizon up to ~2.5 years of follow-up. Only
SES, however, yield a positive incremental effect over the full time
horizon of the analysis (i.e., 3 years). After 2 years, there is a
decline in incremental effects for both DES, which seems to be
driven by a trend toward increased mortality in patients treated
with DES (Fig. 4). Both DES yield a negative incremental net
monetary beneﬁt for time horizons ranging from 0 to 3 years,
assuming a decision maker’s willingness-to-pay of $100,000/
QALY. The cost-effectiveness acceptability frontier is presented
in Figure 5. It provides an estimate of the probability that BMS
are cost-effective and shows that the baseline decision does not
change for the threshold values plotted (Fig. 5).
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Figure 2 Cost-effectiveness plane. Incremental costs and effects of the
sirolimus-eluting (SES) and paclitaxel-eluting stent (PES). First 500 iterations of
5000 Monte Carlo simulations are displayed for each stent. QALYs, quality-
adjusted life-years.
Figure 3 Cost-effectiveness acceptability curves. Base-case analysis with a
time horizon of 3 years. Results are based on 5000 Monte Carlo simulations.
DES, drug-eluting stent; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent.
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The DRG reimbursement rates for BMS and DES clearly
inﬂuence the result. At a difference in DRG reimbursement rates
of less than $3174 (current difference $6760) between BMS and
DES, SES yields a positive INMB (at a willingness-to-pay of
$100,000/QALY), and would therefore be superior to BMS (at a
willingness-to-pay of $50,000/QALY: $3080 for SES and $1901
for PES). At the same threshold level, PES yields a positive INMB
when the difference in reimbursement rates is less than $1816.
DES is then likely to be cost-effective.
In our base-case analysis, we used average DRG reimburse-
ment rates for 10 top-rated US hospitals. In a sensitivity analysis
using average DRG reimbursement rates derived from a random
sample of 10 US hospitals with lower reimbursement rates
(Table 1), there was no qualitative change in our results.
We also explored the robustness of the model toward changes
in quality of life and used the disutility values for PCI and CABG
from a recent health-technology assessment report in the United
Kingdom [39], disregarding long waiting times that are not exis-
tent in the United States. In this sensitivity analysis, model results
did not change the conclusion that would be drawn from the
analysis.
When we applied different commonly used discount rates for
both health effects and costs ranging from 0% to 10%, or when
we used differential discounting (i.e., using a different discount
rate for health effects and costs), we found no major impact on
the results.
Ta
bl
e
3
C
os
ts
,e
ffe
ct
s,
IN
M
B,
an
d
IC
ER
St
en
t
ty
pe
C
os
ts
(U
S$
)
Ef
fe
ct
s
(Q
A
LY
s)
In
cr
em
en
ta
lc
os
ts
(U
S$
)
In
cr
em
en
ta
le
ffe
ct
s
(Q
A
LY
s)
IN
M
B
(u
si
ng
$5
0,
00
0
as
th
re
sh
ol
d)
IN
M
B
(u
si
ng
$1
00
,0
00
as
th
re
sh
ol
d)
IC
ER
(U
S$
/Q
A
LY
)
BM
S
25
,4
65
(2
4,
45
7
to
26
,5
68
)
2.
36
0
(2
.3
24
to
2.
37
9)
SE
S
28
,2
41
(2
7,
61
8
to
28
,9
17
)
2.
36
4
(2
.3
27
to
2.
38
3)
2,
77
5
(1
,4
92
to
3,
98
8)
0.
00
4
(-
0.
04
0
to
0.
04
6)
-2
,5
67
(-
5,
04
1
to
-2
06
)
-2
,3
60
(-
6,
90
2
to
1,
99
2)
66
8,
00
2
PE
S
29
,2
92
(2
8,
59
5
to
30
,0
60
)
2.
36
1
(2
.3
26
to
2.
38
1)
3,
82
7
(2
,5
26
to
5,
10
3)
0.
00
1
(-
0.
04
1
to
0.
04
3)
-3
,7
68
(-
6,
23
4
to
-1
,3
38
)
-3
,7
08
(-
8,
02
1
to
61
9)
>
3,
00
0,
00
0
BM
S,
ba
re
m
et
al
st
en
t;
IC
ER
,i
nc
re
m
en
ta
lc
os
t-
ef
fe
ct
iv
en
es
s
ra
tio
;I
N
M
B,
in
cr
em
en
ta
ln
et
m
on
et
ar
y
be
ne
ﬁt
;P
ES
,p
ac
lit
ax
el
-e
lu
tin
g
st
en
t;
Q
A
LY
,q
ua
lit
y-
ad
ju
st
ed
lif
e-
ye
ar
;S
ES
,s
ir
ol
im
us
-e
lu
tin
g
st
en
t.
Figure 4 Time horizon and incremental effect (QALYs) of the drug-eluting
stents. PES, paclitaxel-eluting stent; QALY, quality-adjusted life-year; SES,
sirolimus-eluting stent.
Figure 5 Cost-effectiveness acceptability frontier. BMS, bare metal stent.
Cost-Effectiveness of Drug-Eluting Stents 653
Discussion
Our results demonstrate that the wide use of DES is not cost-
effective and cannot be advocated for patients with coronary
artery disease similar to those evaluated in the pivotal RCTs
comparing BMS with DES. Interestingly, both types of evaluated
DES showed very small (for SES) or no positive incremental effects
(for PES) when compared with BMS. At the same time, costs
associated with DES are higher than costs associated with BMS,
and therefore DES cannot be considered to be cost-effective.
The strength of our model is the probabilistic approach and
the use of clinical effectiveness data from a large comprehensive
meta-analysis of 17 trials including 8221 patients. The effective-
ness part of our analysis is supported by the recent publications
of individual patient data meta-analyses of trials comparing DES
with BMS [6]. No other cost-effectiveness analysis on DES used
data from such a large number of patients. By relying on clinical
effectiveness data from such a large number of patients, our
model is more precise in predicting clinical outcome events than
other models relying on smaller number of patients. Further-
more, we integrated 3 years of follow-up data into our model.
This is important because differences in need for target vessel
revascularizations between patients treated with DES and BMS
become smaller after the ﬁrst year of stent implantation, whereas
the risk of late stent thrombosis remains constant at a rate of
0.6% per year in patients treated with DES [43]. Therefore, any
cost-effectiveness analysis restricting the time horizon to 1 year
or calculating the cost per revascularizations avoided in the ﬁrst
year clearly results in a biased assessment of the cost-effectiveness
of DES. Many of the included trials intend to follow-up patients
for 5 years after the index procedure. Our analysis based on 3
years of follow-up data may not necessarily be extrapolated to an
extended time horizon because the clinical effectiveness of DES
may differ with longer follow-up.
In our analysis, we explicitly took parameter uncertainty into
account by ﬁtting individual probability distributions to all cost,
quality of life, and epidemiologic parameters in the model. This
allowed us to perform a Monte Carlo simulation that results in
an estimate of the probability that DES is cost-effective for a
given willingness-to-pay value. The uncertainty concerning the
estimates of total health-care costs and total health effects for
both BMS and DES is large. As a consequence, the decision
uncertainty (i.e., the conﬁdence interval for the estimate of the
incremental net monetary beneﬁt) is large as well. Nevertheless,
this has no direct inﬂuence on the conclusion whether DES are
cost-effective or not. In a situation where a decision has to be
taken, the only rational way for a risk-neutral decision-maker is
to adopt the strategy with a positive incremental net monetary
beneﬁt. In our analysis, DES provided a negative INMB and
were thus not cost-effective when compared with BMS at a
willingness-to-pay up to at least $150,000 per QALY (Fig. 3).
Further uncertainty arises through methodological and mod-
eling structure uncertainty, which can be addressed with univari-
ate sensitivity analysis. To assess the inﬂuence of various other
parameters and assumptions on the cost-effectiveness estimate
we performed univariate (i.e., one-way) sensitivity analyses on
various parameters and assumptions. Various sensitivity analyses
did not result in qualitative changes of our results, and the model
proved to be rather robust. Only marked reductions in the dif-
ference of DRG reimbursement rates for BMS and DES inﬂu-
enced the decision in favor of DES.
Our analysis has several limitations. Quality of life data were
not directly obtained from patients enrolled in comparative trials
of DES and BMS, but was derived from the medical literature. To
evaluate the importance of these parameters, we conducted a
sensitivity analysis to evaluate the impact of uncertainty around
quality of life parameters. Using disutility values per event from
a different data source [39] did not change the conclusion of our
analysis. In our base-case, we used the average Medicare reim-
bursement rates and physician fees of 10 top-rated cardiology
hospitals. For this reason, the results of our analysis may seem
limited to patients treated in leading cardiology clinics where
treatment costs are usually higher than in other hospitals. Nev-
ertheless, sensitivity analysis using lower reimbursement rates of
a random sample of 10 US hospitals did not lead to a qualitative
different conclusion of our analysis, and the INMB of DES versus
BMS remained negative, thus increasing the credibility of our
analysis.
Our analysis was mainly based on effectiveness data from
original pivotal trials comparing DES with BMS in patients with
symptomatic ischemic discrete de novo lesions of30-mm length
in native coronary arteries with reference vessel diameters of 2.5 to
3.75 mm (“on-label use”). Nevertheless, it is estimated that 60%
of current DES use in the United States is off-label [44]. Thus, our
ﬁndings cannot easily be generalized to these more complex
patients including patients with acute MI, multiple vessel disease,
and long lesions—lesions involving arterial bifurcations or the left
main coronary artery. The lack of individual patient data pre-
cluded the conduct of subgroup analyses in patients with diabetes
or small vessel disease. Cost-effectiveness analyses in these sub-
groups should deﬁnitely be conducted in the future.
Our study is the ﬁrst cost-effectiveness analysis from a US
third-party payer’s perspective to conclude that the broad use of
DES in patients with coronary artery disease is not cost-effective.
Our ﬁndings are in conﬂict with at least ﬁve cost-effectiveness
analyses from the United States that concluded that DES are
attractive economic interventions [5]. Our results are likely to
differ for mainly two reasons. Our model is the ﬁrst to incorpo-
rate data from a large meta-analysis, including trials identiﬁed by
a systematic, unbiased literature search. In addition, previous
studies have not used a time horizon that is long enough to take
into account the reduced absolute difference in need for target
vessel revascularizations after the ﬁrst year of stent implantation.
Recently, two cost-effectiveness analyses of DES have been
published from a Swiss and a UK perspective. Yet both of these
analyses have their limitations. In the BASKET trial, a single-
center trial with 18 months of follow-up, the incremental cost-
effectiveness ratio of DES was €40,467 per QALY gained [45].
The authors concluded that “DES are not good value for money”
if implanted in unselected patients, but may be cost-effective in
patients with small vessel disease or bypass graft stenting. This
conclusion was based on a subgroup analysis of only 268
patients deemed to be at high risk, with a limited follow-up of 18
months.
In a health-technology assessment report from the United
Kingdom using 12-month clinical follow-up data, DES were not
cost-effective in a typical National Health Service (NHS) popu-
lation, but were considered to be potentially cost-effective in high
risk subgroups [39]. In their analysis, the authors assumed no
difference in mortality between all stent types under analysis.
Nevertheless, from a decision-analytic point of view, even statis-
tically nonsigniﬁcant differences of effects should be incorpo-
rated into an analysis [46]. As mentioned above, lack of
individual patient data precluded us from conducting cost-
effectiveness analyses in high-risk subgroups.
Conclusions
Contrary to other cost-effectiveness analyses conducted from a
US health-care perspective, our analysis from a US Medicare
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perspective suggests that DES are not cost-effective compared
with BMS when implanted in unselected patients with symptom-
atic ischemic coronary artery disease. Whether DES is cost-
effective in certain subgroups needs to be addressed in future
studies. Only if the difference of DRG reimbursement rates for
BMS and DES is markedly reduced can the wide use of DES be
recommended to a large patient population with symptomatic
ischemic coronary artery disease.
Supporting information for this article can be found at: http://
www.ispor.org/publications/value/ViHsupplementary.asp
Source of ﬁnancial support: None.
References
1 Mensah G, Brown D. An overview of cardiovascular disease
burden in the United States. Health Aff (Millwood) 2007;26:38–
48.
2 Al Suwaidi J, Berger P, Holmes D. Coronary artery stents. JAMA
2000;284:1828–36.
3 Serruys P, Unger F, Sousa J, et al. Comparison of coronary-artery
bypass surgery and stenting for the treatment of multivessel
disease. N Engl J Med 2001;344:1117–24.
4 Maisel W. Unanswered questions—drug-eluting stents and the
risk of late thrombosis. N Engl J Med 2007;356:981–4.
5 Ligthart S, Vlemmix F, Dendukuri N, Brophy J. The cost-
effectiveness of drug-eluting stents: a systematic review. CMAJ
2007;176:199–205.
6 Stone G, Moses J, Ellis S, et al. Safety and efﬁcacy of sirolimus-
and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:
998–1008.
7 Babapulle M, Joseph L, Belisle P, et al. A hierarchical Bayesian
meta-analysis of randomised clinical trials of drug-eluting stents.
Lancet 2004;364:583–91.
8 Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of
data comparing sirolimus-eluting stents with bare-metal stents. N
Engl J Med 2007;356:989–97.
9 Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: a rapid
systematic review and economic evaluation. Health Technol
Assess 2004;8:iii–242.
10 Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials compar-
ing sirolimus-eluting stents with bare-metal stents. N Engl J Med
2007;356:1030–9.
11 Nordmann A, Briel M, Bucher H. Mortality in randomized con-
trolled trials comparing drug-eluting vs. bare metal stents in
coronary artery disease: a meta-analysis. Eur Heart J 2006;27:
2784–814.
12 Katritsis D, Karvouni E, Ioannidis J. Meta-analysis comparing
drug-eluting stents with bare metal stents. Am J Cardiol 2005;95:
640–3.
13 Brophy J, Erickson L. Cost-effectiveness of drug-eluting coronary
stents in Quebec, Canada. Int J Technol Assess Health Care
2005;21:326–33.
14 Bagust A, Grayson A, Palmer N, et al. Cost effectiveness of drug
eluting coronary artery stenting in a UK setting: cost-utility study.
Heart 2006;92:68–74.
15 Kaiser C, Brunner-La Rocca H, Buser P, et al. Incremental cost-
effectiveness of drug-eluting stents compared with a third-
generation bare-metal stent in a real-world setting: randomised
Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;
366:921–9.
16 Lord S, Howard K, Allen F, et al. A systematic review and eco-
nomic analysis of drug-eluting coronary stents available in Aus-
tralia. Med J Aust 2005;183:464–71.
17 Shrive F, Manns B, Galbraith P, et al. Economic evaluation of
sirolimus-eluting stents. CMAJ 2005;172:345–51.
18 Hout B, Serruys P, Lemos P, et al. One year cost effectiveness of
sirolimus eluting stents compared with bare metal stents in the
treatment of single native de novo coronary lesions: an analysis
from the RAVEL trial. Heart 2005;91:507–12.
19 Ryan J, Cohen D. Are drug-eluting stents cost-effective? It
depends on whom you ask. Circulation 2006;114:1736–43.
20 Eisenberg M. Drug-eluting stents: the price is not right. Circula-
tion 2006;114:1745–54.
21 Ruffy R, Kaden RJ. Projected health and economic beneﬁts of the
use of sirolimus-eluting coronoary stents. Adv Stud Med 2003;
3(6D):602–11.
22 Greenberg D, Bakhai A, Cohen D. Can we afford to eliminate
restenosis? Can we afford not to? J Am Coll Cardiol 2004;43:
513–18.
23 Greenberg D, Cohen D. Examining the economic impact of res-
tenosis: implications for the cost-effectiveness of an antiprolifera-
tive stent. Z Kardiol 2002;91(Suppl.):3137–143.
24 Cohen D, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-
eluting stents for treatment of complex coronary stenoses: results
from the Sirolimus-Eluting Balloon Expandable Stent in the
Treatment of Patients With De Novo Native Coronary Artery
Lesions (SIRIUS) trial. Circulation 2004;110:508–14.
25 Bakhai A, Stone G, Mahoney E, et al. Cost effectiveness of
paclitaxel-eluting stents for patients undergoing percutaneous
coronary revascularization: results from the TAXUS-IV trial.
J Am Coll Cardiol 2006;48:253–61.
26 Sculpher M, Claxton K, Drummond M, McCabe C.
Whither trial-based economic evaluation for health care decision
making? Health Econ 2006;15:677–87.
27 Sonnenberg F, Beck J. Markov models in medical decision
making: a practical guide. Med Decis Making 1993;13:322–38.
28 Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analy-
sis, 2nd edn. London, UK: Chapman & Hall/CRC, 2003.
29 Hankey G, Jamrozik K, Broadhurst R, et al. Five-year survival
after ﬁrst-ever stroke and related prognostic factors in the Perth
Community Stroke Study. Stroke 2000;31:2080–6.
30 Furman M, Dauerman H, Goldberg R, et al. Twenty-two year
(1975 to 1997) trends in the incidence, in-hospital and long-term
case fatality rates from initial Q-wave and non-Q-wave myocar-
dial infarction: a multi-hospital, community-wide perspective.
J Am Coll Cardiol 2001;37:1571–80.
31 Witt B, Brown R, Jacobsen S, et al. A community-based study of
stroke incidence after myocardial infarction. Ann Intern Med
2005;143:785–92.
32 Serruys P, Ong A, van Herwerden L, et al. Five-year outcomes
after coronary stenting versus bypass surgery for the treatment of
multivessel disease: the ﬁnal analysis of the Arterial Revascular-
ization Therapies Study (ARTS) randomized trial. J Am Coll
Cardiol 2005;46:575–81.
33 Hellermann J, Jacobsen S, Redﬁeld M, et al. Heart failure after
myocardial infarction: clinical presentation and survival. Eur J
Heart Fail 2005;7:119–25.
34 Hannan E, Racz M, Walford G, et al. Long-term outcomes of
coronary-artery bypass grafting versus stent implantation. N Engl
J Med 2005;352:2174–83.
35 Centers for Medicare & Medicaid Services [Internet]. Available
from: http://www.cms.hhs.gov/ [Accessed February 15, 2008].
36 Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-
effectiveness of early and sustained clopidogrel therapy for up to
1 year in patients undergoing percutaneous coronary intervention
after presenting with acute coronary syndromes without
ST-segment elevation. Am Heart J 2006;151:219–27.
37 Best Hospitals 2007 specialty search: heart [Internet]. Available
from: http://health.usnews.com/usnews/health/best-hospitals/
search.php?spec=ihqcard& [Accessed April 22, 2008].
38 Lacey EA, Walters SJ. Continuing inequality: gender and social
class inﬂuences on self perceived health after a heart attack. J
Epidemiol Community Health 2003;57:622–7.
39 Hill RA, Boland A, Dickson R, et al. Drug-eluting stents: a sys-
tematic review and economic evaluation. Health Technol Assess
2007;11:iii, xi–221.
40 Stinnett A, Mullahy J. Net health beneﬁts: a new framework for
the analysis of uncertainty in cost-effectiveness analysis. Med
Decis Making 1998;18(2 Suppl.):S68–80.
Cost-Effectiveness of Drug-Eluting Stents 655
41 Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity
analysis for NICE technology assessment: not an optional extra.
Health Econ 2005;14:339–47.
42 Briggs A. Handling uncertainty in cost-effectiveness models. Phar-
macoeconomics 2000;17:479–500.
43 Daemen J, Wenaweser P, Tsuchida K, et al. Early and
late coronary stent thrombosis of sirolimus-eluting and
paclitaxel-eluting stents in routine clinical practice: data from
a large two-institutional cohort study. Lancet 2007;369:667–
78.
44 FDA. Update to FDA Statement on Coronary Drug-Eluting
Stents. Available from: http://www.fda.gov/cdrh/news/010407.
html [Accessed February 15, 2008].
45 Brunner-La Rocca HP, Kaiser C, Bernheim A, et al. Cost-
effectiveness of drug-eluting stents in patients at high or low
risk of major cardiac events in the Basel Stent KostenEffektivitäts
Trial (BASKET): an 18-month analysis. Lancet 2007;370:1552–9.
46 Claxton K. The irrelevance of inference: a decision-making
approach to the stochastic evaluation of health care technologies.
J Health Econ 1999;18:341–64.
656 Bischof et al.
